RussianPatents.com

Agent normalising liver mitochondria. RU patent 2470655.

FIELD: medicine.

SUBSTANCE: invention refers to medicine, more specifically pharmacology. Grape seed extract is presented as an agent normalising liver mitochondria.

EFFECT: grape seed extract maximally improves liver bioenergy, increases succinate dehydrogenase activity, rate of oxygen uptake by mitochondria and conjugation of oxidative phosphorylation.

1 ex, 4 tbl

IPC classes for russian patent Agent normalising liver mitochondria. RU patent 2470655. (RU 2470655):

A61P1/16 - for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

A61K36/21 - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J0003000000; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L)

Another patents in same IPC classes:

Agent possessing antiarrhythmic and hepatoprotective properties / 2469720
Invention refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide of formula I: as an agent possessing antiarrhythmic and hepatoprotective properties. The invention also refers to the use of 9-(2-diethylaminomethyl)-2-(3,4-dioxyphenyl)imidazo[1,2-a]benzimidazole dihydrobromide for preparing pharmaceutical compositions.

Use of polydatine for treating hepatic diseases and polydatine pharmaceutical composition / 2468803
There are presented the use of polydatine for treating toxic (including drug-induced) and alcoholic hepatic diseases, as well as based oral compositions. What is shown is reduction of a degree of hepatocyte adipose degeneration in sub-acute alcoholisation, reduction of glycemia and lactate-acidosis. Polydactine promoted reduction of synthesis and accumulation of glycosaminoglycans.

Method of preventing chronic toxic hepatopathy / 2468446
In order to prevent chronic toxic hepatopathy melaxen is introduced to animals in experiment one time per day in dose 10 mg/ml through probe into stomach. Simultaneously intragastric introduction of cobalt chloride solution in dose 2 mg/kg, in terms of metal, is performed daily, to create cobalt intoxication in organism.

Method for preparing agent showing cholagogue action / 2465000
Invention refers to pharmaceutical industry, specifically to an agent showing cholagogue action. A method for preparing the agent showing cholagogue action consisting in the fact that ground sandy everlasting blossom, nosebleed herb and peppermint leaves are mixed with coriander fruit, extracted in 40% ethanol by multistage counterflow extraction, settled, filtered, condensed under certain conditions.

Quinazoline derivative and pharmaceutical preparation / 2464263
Invention relates to a quinazoline derivative of general formula [1], or a pharmaceutically acceptable salt thereof [1], where R1-R6 assume values given claim 1, except compounds in which R5 is hydrogen and R6 is -NH2. The invention also relates to a pharmaceutical composition having the activity of an antipruritic agent, containing as an active ingredient said quinazoline derivative or pharmaceutically acceptable salt thereof.

Agent of saussurea ds plants possessing hepatoprotective action / 2464036
Invention refers to pharmaceutical industry, particularly to an agent possessing hepatoprotective activity and an ability to normalise the hepatic function. The use of a ground elevated part of Saussurea plants or an aqueous or aqueous-alcoholic or supercritical fluid extract of the elevated part of Saussurea plants as the agent possessing hepatoprotective activity and the ability to normalise the hepatic function.

Use of modified cyclosporines / 2463071
Group of inventions refers to medicine, particularly the use of non-immunosuppressive cyclophilin-binding cyclosporine for preventing or treating transplantation-related cirrhosis wherein cyclosporine (I) binds to human recombinant cyclophilin with a binding constant (BR) making less than 0.7 wherein BR represents a common logarithm of IC50 cyclosporine to IC50 cyclosporine A relation in concurrent experiment when evaluating by ELISA procedure; and (II) has activity in lymphocyte assay in the mixed culture making no more than 5% as compared with cyclosporine A activity (cl. 1) of the patent claim. There are also disclosed a pharmaceutical composition and a pharmaceutical combination containing cyclosporine under cl. 1.

Phospholipid nanoform for oral application (sachet) and method for preparing it (versions) / 2463057
Invention refers to medicine, pharmacology and concerns an oral granulated dosage form in sachets containing phospholipids in the form of particles of small (20-30 nm) diameter, glycyrrhizic acid and its salt (including sodium glycerrhizinate), as well as carbohydrate (including maltose) and excipients (granulation, anti-clotting and powder), as well as to a method for preparing it by mixing fat and water phases of herbal phospholipids and acceptable carbohydrate to prepare an emulsion, cooling to 50°C and passing through a microfluidiser for 4-5 cycles under pressure 2000 atm.

Agent showing hepatoprotective action, and method for preparing it / 2462259
Invention refers to pharmaceutical industry, specifically to an agent showing hepatoprotective action. The agent showing hepatoprotective action of a herbal polyphenol extract of Amur maackia heartwood (Maxar) which represents an aqueous solution of Maxar in the molecular-capsulated form in the form of a water-soluble associated with a surfactant having a specific hydrophilic-lipophilic balance. A method for preparing the agent showing hepatoprotective action by Maxar homogenisation in the melt surfactant under certain conditions to produce the molecular-capsulated form of the end product.

Method of treating patients with chronic liver diseases in stage of latency and degree i manifested stage of hepatic encephalopathy / 2462251
Invention refers to medicine and aims at treating the patients with chronic liver diseases (CLD) in the stage of latency and degree I manifested stage of hepatic encephalopathy. The preparation Essentiale forte N is used. It is combined with prescribing the preparation Mucofalk. The course is 28-30 days.

Method of treating oral candidosis by complex phytopreparation / 2470654
Invention refers to medicine and aims at treating oral candidosis. What is used is medical oil produced by olive oil recovery (in proportions of oil-raw material (1:10) of the herbal infusion from Rhaponticum carthamoides root and rhizome or campion herb, calendula blossom, celandine herb taken in equal weight proportions. The oil is applied on oral mucosa in the form of applications three times a day for 14 days. The patients are recommended to abstained from food and water intake for one hour after removal of the applicator.

Agent for burn and wound healing / 2470653
Invention refers to pharmaceutical industry, particularly to a medicine for treating depression. An agent for burn and wound healing containing aqueous Siberian larch extract prepared by bioresonance procedure, containing 0.002% of dihydroquercetin of certain particle size and water in certain proportions.

Use of agglomerate-forming hydroxyethyl cellulose for producing pharmaceutical agents, personal hygiene products and household supplies / 2470626
Invention refers to chemical-pharmaceutical industry and represents a consumer product containing: a composition of agglomerate-forming hydroxyethyl cellulose (HEC), an active ingredient of the consumer product and water, wherein the composition of agglomerate-forming hydroxyethyl cellulose contains hydroxyethyl cellulose particles and a composition of low-molecule hydroxyethyl cellulose, and wherein the consumer product is specified in a group involving pharmaceutical preparations, personal hygiene products (except for those for oral application) and household supplies, and wherein low-molecule hydroxyethyl cellulose has molecular weight less than hydroxyethyl cellulose particles, and they are characterised by viscosity less than 350 mPa·s (cP) in 2% aqueous solution.

Oil-in-water emulsion, ph 3-5,5 / 2470625
Invention refers to cosmetic industry and represents a cosmetic composition in the form of an oil-in-water emulsion formed by oil globules each of which has a liquid-crystalline lamellar coating, dispersed in an aqueous phase, differing by the fact that it has pH 3-5 and contains at least one lipophilic surfactant with HLB equal to 2-5, at least one hydrophilic surfactant with HLB equal to 8-12, and at least one amphiphilic compound having an ionic form at pH 3-5.5.

Method of automatic assessment of skin and/or wrinkle texture / 2470576
Group of inventions relates to cosmetology. Method includes stages at which processing of skin image is performed, which includes cross conversion to binary form and/or processing by comparison of short linear segments to obtain 10 or more types of physical parameters, related to dermal furrow; then physical parameters, obtained at previous stage are substituted into prediction formula. Prediction formula is determined by multi-variant analysis of 10 or more types of physical parameters, related to dermal furrow, and visual assessment values, distributes by categories from third to tenth degree, related to skin and/or wrinkle, obtained from a number of samples in order to obtain assessment value by categories from 3 to 10 degree and assessment of obtained assessment value as assessment result with respect to skin and/or wrinkle texture. Described are device for assessment of skin texture and method of selecting medication for external application on skin, which uses assessment method or device.

Method of deliverance from alcohol abuse / 2469749
Patient is helped out of the state of alcohol abstinence, rational psycho-correction aimed at complete deliverance from addiction is performed. Negative conditioned reflex to alcohol is formed and fixed by step-by-step reduction of its intake by laminar turbulence and jet oscillatory instillation of drink into mouth and pharynx cavity. For this purpose used is narrowing vessel with flexible nozzle with 45-60° angle of inclination of nozzle outlet canal with respect to vessel axis and ratio of lengths of initial inlet section - to the middle of nozzle turn and terminal outlet section equal 1.618, ratio of nozzle diameter to nozzle length equal 0.04-0.08. Patient is isolated for the moment of alcohol intake by seclusion and light and sound insulation, amount of taken-in alcohol is reduced with each following intake by two fold reduction of alcohol concentration from the initial one by dilution with drinkable water with dissolution of 5 drops of 62% stevia extract and 0.1-0.2 g of sea table salt per 200 ml of drink. Before intake rink is heated to 39-41°C on water bath, frequency of swallows is increased with reduction of each swallow volume until disgust to alcohol and process of intake develops. Self-control of disgust degree and self-regulation of amount and volume of swallows are carried out. When stable disgust to alcohol, its smell and taste, process of its intake in form of its nausea-vomiting response, abundant saliva, sweating, weakness in legs, is achieved, intake is completely stopped. In the process of method implementation, lectures about alcohol harm, daily filling in of the table of observations with dynamics analysis, conclusions, plan for the future, self-healthrestoring procedures are carried out.

Method of carrying out of superovulation in cows-donors of embryos / 2469738
Method includes injection of the preparation "FSH-super" and the preparation of prostaglandin F2α. On the day of artificial insemination the cows-donors are additionally injected with homeopathic preparation "Ovariovit" at the dose of 4.9-5.1 ml per head in a single dose.

Medication for treating accommodation disorders "stiak" / 2469734
Method of treating accommodation disorders, including introduction of morning and evening compositions into conjunctival sac, with morning composition containing cytidine or digoxin, taufon or taurine, polyvinylpyrrolidone, menthol and rose water, and evening composition containing tropicamide, mezaton, digoxin or adenosine triphosphate, menthol and rose water and carrying out additionally aromatherapy with application of morning and evening compositions of essential oils, with morning composition containing essential oils of rosemary, lemon and geranium, and evening composition containing essential oils of bergamot, jasmine and orange, with specified component ratio.

Amino acid preparation eliciting antitumor effect and method for its preparing / 2245143
Invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.